<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878563</url>
  </required_header>
  <id_info>
    <org_study_id>2017-00249</org_study_id>
    <nct_id>NCT03878563</nct_id>
  </id_info>
  <brief_title>Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial (AMBIC)</brief_title>
  <acronym>AMBIC</acronym>
  <official_title>Alterations in Intestinal Mucosal Barrier Visualized by Confocal Laser Endomicroscopy in Liver Cirrhosis: a Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr.med. Monica Rusticeanu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spital Limmattal Schlieren</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial with medical devices. A diagnostic trial conducted to find a better (less
      invasive) procedure for predicting the onset of spontaneous bacterial peritonitis(SBP), which
      is a complication of liver cirrhosis with ascites.The current recommendation for primary
      prophylaxis of SBP include a low protein content of the ascitic fluid or a gastrointestinal
      bleeding. This trial will use the CLE (confocal laser endomicroscopy) technic in order to
      quantify the intestinal permeability in patients with liver cirrhosis and correlate this to
      the onset of spontaneous bacterial peritonitis.We aim to evaluate a new diagnostic tool (the
      confocal laser endoscopy(CLE) technique -cellvizio- in the setting of endoscopy and defining
      parameters that are altered in cirrhotic patients of different severity and being at risk of
      developing a SBP (spontaneous bacterial peritonitis).The parameters assessed by confocal
      laser endomicroscopy will be correlated with the protein content in ascitic fluid and the
      patient will be monitored for time to occurrence of spontaneous bacterial peritonitis.

      Defining a correlation between the quantified loss of intestinal integrity and i) total
      protein concentration in the ascitic fluid and ii) stadium of liver disease (Child class A, B
      or C)
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor-PI left Switzerland
  </why_stopped>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">June 20, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of spontaneous bacterial peritonitis at 12 months</measure>
    <time_frame>24 months</time_frame>
    <description>The parameters assessed by confocal laser endomicroscopy will be correlated with the protein content in ascitic fluid and the patient will be monitored for occurrence of spontaneous bacterial peritonitis for the next 12 months.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Liver Cirrhoses</condition>
  <arm_group>
    <arm_group_label>ascites with/without SBP</arm_group_label>
    <description>Cirrhosis with ascites and existing SBP or prior SBP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ascites and decreased protein concentrati</arm_group_label>
    <description>Cirrhosis with ascites and decreased protein concentration &lt;1,5 g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ascites and normal protein concentration</arm_group_label>
    <description>Liver cirrhosis witha scites and protein concentration &gt;1,5 g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver cirrhosis without ascites</arm_group_label>
    <description>Patients with liver corrhosis without ascites</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls without liver cirrhosis or other pathology</arm_group_label>
    <description>Healthy pacients (without chronic disease) undergoing screening coloscopy or gastroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cellvisio 100 Series (fibered confocal microscopic system)</intervention_name>
    <description>This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.
An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.</description>
    <arm_group_label>Healthy controls without liver cirrhosis or other pathology</arm_group_label>
    <arm_group_label>Liver cirrhosis without ascites</arm_group_label>
    <arm_group_label>ascites and decreased protein concentrati</arm_group_label>
    <arm_group_label>ascites and normal protein concentration</arm_group_label>
    <arm_group_label>ascites with/without SBP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with liver cirrhosis and healthy controls, older than 18 years and younger than 80
        years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Adult individual (&gt;18yo) with liver cirrhosis of any cause and healthy controls undergoing
        elective endoscopy

        Exclusion Criteria:

          -  Patients younger than &lt; 18, older than 80 years

          -  Pregnant or breastfeeding women

          -  Known allergy to fluorescein.

          -  Cardiac disease

          -  Asthma bronchiale

          -  Patients with inability or unwillingness to provide blood samples or samples of
             ascitic fluid.

          -  patients unable to give informed consent

          -  non-resident patients

          -  contraindication for an endoscopic examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Limmattal Spital</name>
      <address>
        <city>Schlieren</city>
        <state>Zürich</state>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Spital Limmattal Schlieren</investigator_affiliation>
    <investigator_full_name>Dr.med. Monica Rusticeanu</investigator_full_name>
    <investigator_title>Dr.med. M. Rusticeanu LÄ stv. Gastroenterologie und Hepatologie</investigator_title>
  </responsible_party>
  <keyword>intestinal barrier dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

